FDA Responds To Antidepressant Inquiry, Says All Data Properly Disclosed
Executive Summary
Conclusions about a link between antidepressants and suicidal behavior by an FDA safety reviewer were not presented at a Feb. 2 advisory committee because they did not concur with the agency's findings, FDA said
You may also be interested in...
Antidepressant Investigations Continue; GAO Studying FDA Process
The Government Accountability Office is studying how FDA resolves internal disputes about drug safety issues
Antidepressant Investigations Continue; GAO Studying FDA Process
The Government Accountability Office is studying how FDA resolves internal disputes about drug safety issues
GSK Posts Paxil Pediatric Data On Website; Plans U.S. Clinical Trial Register
GlaxoSmithKline's off-the-shelf response to requests for information about off-label use of Paxil in pediatric patients notes that there are studies demonstrating efficacy of paroxetine in obsessive/compulsive disorder and social anxiety disorder